News

Brise Pharmaceuticals Co., Ltd. (Brise), a clinical-stage biopharmaceutical company focused on developing innovative therapies for pain management, today announced the completion of a Series A financing of more than $30 million.
The financing was led by Beijing Medical and Health Care Industry Investment Fund, with participation from INCE Capital, Chengdu Guanghua Wutong Equity Investment Fund and Proxima Capitals. Existing investors Shunxi Fund and Qiming Venture Partners also participated in the round.
The proceeds will primarily support the planned pivotal Phase III clinical study of BR005, an independently developed small-molecule calcitonin gene-related peptide receptor(CGRPR)-targeted drug candidate, and the continued expansion of the Company's innovative pain management pipeline.

Brise Pharma was recently named one of China’s Top 15 Emerging Innovative Drug Companies of 2025 by PharmaCube. The annual ranking was announced during the 2026 One BD Pharmaceutical Investment, Financing and Business Development Conference held in Shanghai.

Recently, Brise Pharmaceuticals Co. Ltd. announced that Dr. Danny Chen has joined the company as Research and Development President of the group company, and Chief Executive Officer of the US subsidiary.

Brise Pharmaceuticals Co., LTD. (Brise), a pioneering company specializing in innovative treatments for acute and chronic pain, has recently completed Pre-A and Pre-A+ financing with a total of approximately $20 million. This Pre-A round is led by Shunxi Fund, followed by Cnfuel Capital, Vinner Therapeutics and existing investors such as Qiming Venture Partners and BioTrack Capital. The Pre-A+ round is exclusively invested by Sherpa Healthcare Partners.

Brise Pharmaceuticals Co., LTD., a pioneering company specializing in innovative treatments for chronic pain, has taken a significant step forward with the commencement of dosing for the initial participants in its Phase 1 clinical trial, designated MBR01T-101. The trial focuses on the safety and tolerability study of BR01T, a groundbreaking monoclonal antibody designed to target Tropomyosin Receptor Kinase (TrkA) for addressing Chronic Low Back Pain (CLBP).

Brise Pharmaceuticals Co., LTD., a pioneering company specializing in innovative treatments for chronic pain, announced that the company’s pipeline BR007 has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of Camurati-Engelmann disease (CED). BR007 is a small molecule-drug conjugate with bone-targeting properties that specifically inhibits the TGF-β receptor in bone tissue cells. BR007, by avoiding non-specific systemic inhibition of TGF-β, will prevent multiple serious side effects.

Brise Pharmaceuticals Co., LTD., an emerging company specializing in innovative treatments for chronic pain, announced that it has raised $20 million in angel funding. The round was co-led by Qiming Venture and BioTrack Capital, with participation from Sinopharm Capital. Brise Pharma aims to be a global leader in innovative pain treatment by providing safe, effective and accessible pain management solutions to patients worldwide who suffer from debilitating pain conditions through relentless innovation.